Skip to content
Simpler Grants

No. PAR-25-141 · National Institutes of Health

Open

NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)

grants.gov listing Full announcement (NOFO)
Dealbreakers No cost share required Audit: not stated Reimbursement-only: not stated
Award range
Not specified
Expected awards
Not specified
Application deadline
Mar 4, 2027
Posted
Dec 9, 2024
Last verified
7 days ago

At a glance

AI summary

This program funds two-phase cooperative agreements for clinical trials on arthritis, musculoskeletal, or skin diseases and disorders, including prevention, treatment, safety, efficacy, effectiveness, and behavior-change studies. Applicants must propose a clinical trial, and foreign organizations and non-domestic components of U.S. organizations are not eligible to apply, though foreign components are allowed. The UG3 phase is limited to $250,000 in direct costs, while the UH3 phase has no set budget cap; the total project period can be up to six years. No cost sharing is required.

AI-generated summary — verify against the announcement

What it funds

  • Health
  • Research & Discovery
  • Researchers & Scholars
  • Biomedical & Disease Research
Official description from grants.gov

This NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required) PAR, a re-issue of PAR-24-208, was re-issued as a result of the Simplifying Review of Research Project Grant Applications [link: https://grants.nih.gov/policy-and-compliance/policy-topics/peer-review/simplifying-review]. The Simplified Review changes in Section V. Application Review Information of the funding opportunity are the only changes that have been made. All other aspects of this funding opportunity remain the same.

Who can apply

  • City or township governments
  • County governments
  • For-profit organizations other than small businesses
  • Independent school districts
  • Native American tribal governments (Federally recognized)
  • Native American tribal organizations (other than Federally recognized)
  • Nonprofits with 501(c)(3) status (other than higher education)
  • Nonprofits without 501(c)(3) status (other than higher education)
  • Others
  • Private institutions of higher education
  • Public and State controlled institutions of higher education
  • Public housing authorities / Indian housing authorities
  • Small businesses
  • Special district governments
  • State governments
Geographic restriction None found in the announcement — likely nationwide

Program history

USASpending.gov

Assistance listing 93.846 · Arthritis, Musculoskeletal and Skin Diseases Research

Real awards this federal program has made — the whole assistance listing (93.846), not just this notice.

Fiscal year Awards Median award Middle half
FY 2026 (so far) 148 $377,506 $124,696 – $576,799
FY 2025 274 $432,326 $224,620 – $1,053,137
FY 2024 357 $473,099 $306,518 – $1,364,153
FY 2023 400 $611,188 $300,000 – $1,870,687
FY 2022 420 — —
FY 2021 357 — —

Dollar figures are based on the 1,000 most recent awards we store, not all 1,956 — award counts are complete.

Who wins it Higher education (1,364), Nonprofit (386), Business (144) of 1,956 awards — categories can overlap.
Top states CA (115) · MA (97) · NY (92) · PA (78) · NC (52)
Largest recent awards
  1. WAKE FOREST UNIVERSITY $10,449,074 · FY 2023
  2. THE GENERAL HOSPITAL CORPORATION $5,795,791 · FY 2023
  3. REGENTS OF THE UNIVERSITY OF MICHIGAN $3,579,362 · FY 2023
  4. VANDERBILT UNIVERSITY MEDICAL CENTER $3,213,591 · FY 2026
  5. UNIVERSITY OF ALABAMA AT BIRMINGHAM $3,106,910 · FY 2023

Source: USASpending.gov · refreshed Aug 23, 2026